FIBROGEN, INC.

FGEN

Delayed - 01/15 04:00:00 pm
43.23USD	+0.39%

Turn to zoom

Prev.	43.0600
Open	42.5700
High	44.3600
Low	41.3800
Volume	1 752 357

01/08	Insider Trends: Insider at FibroGen Sells Stock for Taxes Interrupting...
12/22	FibroGen : Commences Phase 3 Trial of Pamrevlumab in Idiopathic Pulmonary...
12/22	FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the...
12/21	Stocks Dragged Into The Red as New COVID-19 Strain From UK Prompts Travel...

	Short Term	Mid-Term	Long Term
Trend	Neutral	Neutral	Bullish
Resistance	44,2	49,0	48,8
Spread/Res.	-2,3%	-12%	-11%
Spread/Supp.	17%	17%	24%
Support	37,1	37,1	35,0

Sales 2020	217 M - -
Net income 2020	-158 M - -
Net Debt 2020	- - -
P/E ratio 2020	-25,6x
Yield 2020	-

Capitalization	3 934 M 3 934 M -
Capi. / Sales 2020	18,1x
Capi. / Sales 2021	8,25x
Nbr of Employees	531
Free-Float	91,9%

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines...

>> Read more

Sector :

Biotechnology & Medical Research - NEC

Calendar :

2021-03-03 Earnings Release

Trading Rating :

Investor Rating :

Mean consensus	OUTPERFORM
Number of Analysts	10
Average target price	61,88 $
Last Close Price	43,23 $
Spread / Highest target	111%
Spread / Average Target	43,1%
Spread / Lowest Target	1,78%